Welcome to our dedicated page for Biolargo news (Ticker: BLGO), a resource for investors and traders seeking the latest updates and insights on Biolargo stock.
Stay informed about developments from BioLargo, Inc., a cleantech and environmental technology company advancing solutions for PFAS water treatment, energy storage, medical devices, and consumer products. News coverage typically focuses on the company's technology milestones, commercial partnerships, regulatory approvals, and market expansion activities across its multiple business segments.
Water treatment announcements often detail advancements in the company's AEC technology for PFAS removal, including system installations, performance validations, and partnerships with municipal or industrial clients. Energy storage news covers progress in Cellinity battery development, joint venture discussions, pilot facility operations, and applications for grid-scale storage projects. Medical device updates track the development and distribution partnerships for Bioclynse and other infection control products targeting surgical and wound care markets.
Corporate news includes financial performance reports, stock exchange listing developments, patent grants and intellectual property milestones, strategic partnerships and licensing agreements, and management commentary on business segment performance. Consumer product announcements highlight retail distribution expansions, product line extensions, and market reception for the Pooph brand and other direct-to-consumer offerings.
Regulatory and compliance news may cover environmental regulations affecting target markets, EPA standards for PFAS treatment, product certifications and testing results, and industry studies validating the company's technologies. Given BioLargo's focus on emerging environmental challenges and evolving regulatory frameworks, news flow often reflects the intersection of environmental policy, technological innovation, and commercial deployment across water treatment, energy storage, and healthcare sectors.
BioLargo's subsidiary, Clyra Medical Technologies, has selected Keystone Industries to support the manufacturing of its medical products, specifically the Bioclynse surgical wound irrigation solution. Bioclynse is FDA 510(k) cleared, non-cytotoxic, and effective against biofilms, presenting significant benefits for patient outcomes in surgeries and dentistry. Keystone, a global manufacturer with over a century of experience, has committed significant investment in infrastructure to scale up production. Both companies have emphasized the importance of this collaboration for the successful market launch of Bioclynse.
BioLargo (OTCQX:BLGO) has successfully manufactured its first Cellinity™ 'Liquid Sodium' prototype battery cells. The Cellinity battery platform aims to provide safer, long-lasting, and environmentally friendly energy storage alternatives to lithium-ion batteries. These prototype cells will undergo testing and validation to confirm performance claims. Cellinity batteries boast several advantages: safety (no fire or explosion risk), longevity (no performance drop after thousands of cycles), high energy density, and the use of North American-sourced materials without rare-earth elements. Future plans include manufacturing full-scale prototype modules and exploring financing options, focusing on community-based partnerships.
BioLargo (OTCQX:BLGO) announced that its engineering subsidiary has secured a multi-year contract to provide air quality services to three U.S. Air Force bases in New Mexico. The contract, potentially generating $650,000 annually, spans up to five years and represents the company's largest Air Force contract to date. This new agreement adds to BioLargo's ongoing environmental support at six other Air Force bases. The contract ensures regular monthly flat fee revenue over its duration, with annual renewal options. Bhate Environmental Associates is the prime contractor under the Fence-to-Fence (F2F) support contract. BioLargo's President, Randall Moore, emphasized the importance of such long-term contracts for steady income and the commercialization of their cleantech innovations.
BioLargo (OTCQX:BLGO) reported positive operating cash flow of $481,000 and record quarterly revenues of $4,760,000 for Q1 2024, reflecting a 9% increase over Q4 2023 and a 28% increase over Q1 2023. The company's net stockholder's equity rose from $4.2 million to $5.1 million. Despite a net loss of $775,000, this represents a 32% decrease compared to the prior quarter. Significant business developments include launching a water equipment subsidiary and securing key industry leaders on its board. The U.S. EPA's new PFAS regulations could benefit BioLargo's technology. The company continues to invest in scaling up its Bioclynse product line.
BioLargo, Inc. (BLGO) will host an investor webcast and conference call on May 14, 2024, to discuss financial results for Q1 2024, recent milestones, and conduct a Q&A session. The event will be open to the public, covering sustainable technologies for environmental challenges.
FAQ
What is the current stock price of Biolargo (BLGO)?
What is the market cap of Biolargo (BLGO)?
